Company overview
Crown Bioscience is a global contract research organization providing integrated biomarker services, preclinical models, and translational platforms for pharmaceutical and biotechnology companies. The company offers tissue-based analysis, genomics, proteomics, and comprehensive bioinformatics services across in vivo, in vitro, ex vivo, and in silico platforms. Crown operates over 800 organoid models and 2,700 PDX models enhanced by biomarker analysis, supporting drug efficacy assessment and pharmacological profiling from discovery through clinical trial readiness.
Biomarker & Preclinical Drug Development Services is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, Diagnostics & Testing partner serving United States & Americas. Core focus areas include biomarker services, preclinical models, pdx xenografts, organoid screening, genomics sequencing, biospecimen biobank.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Biomarker & Preclinical Drug Development Services include Cro — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.crownbio.com
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- biomarker services, preclinical models, pdx xenografts, organoid screening, genomics sequencing, biospecimen biobank, translational research, drug development cro, oncology research, precision medicine
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What biomarker services does Crown Bioscience provide?
- Crown Bioscience offers comprehensive clinical biomarker services including tissue-based analysis (IHC, multiplex immunofluorescence, spatial transcriptomics, digital pathology), genomics and transcriptomics (NGS, RNA sequencing), proteomics and immunology assays (ELISA, multiplex immunoassays, cytokine profiling), and bioinformatics data analysis. The company maintains over 500 prequalified biomarkers, including 100+ IVD-validated assays.
- What preclinical models and platforms does Crown Bioscience offer?
- Crown Bioscience provides in vivo, in vitro, ex vivo, and in silico preclinical models, including patient-derived xenografts (PDX), cell line-derived xenografts (CDX), organoids, and 3D models. The company operates over 800 organoid models and 2,700 PDX models that can be integrated with comprehensive biomarker analysis for high-throughput screening and translational research.
- Does Crown Bioscience provide human biospecimens and biobank services?
- Yes, Crown Bioscience offers globally-sourced, IRB-approved human biospecimen solutions including FFPE and fresh frozen tissues, custom collections, and CAP-accredited pathology services. Their biobank includes high-quality tumor tissue, matched adjacent normal samples, plasma, serum, and PBMCs collected under standardized protocols with ultra-short ischemia times, paired with extensive clinical data.
- What is Crown Bioscience's regulatory status and quality standards?
- Crown Bioscience maintains CAP-accredited pathology services and operates under IRB-approved protocols for biospecimen collection. The company is a qualified CRO service provider for spatial phenotyping techniques and offers IVD-validated assays designed to support clinical trial readiness.
- What therapeutic areas does Crown Bioscience support?
- Crown Bioscience supports drug development across all clinical phases and therapeutic areas, with particular expertise in oncology. The company specializes in precision medicine solutions and has developed capabilities specifically for ADC (antibody-drug conjugate) development and translational oncology research.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
